Get started
Author

A. D. Borowsky

Abstract PD10-02: I- SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant vepdegestrant monotherapy or in combination with letrozole or abemaciclib in molecularly selected patients with stage 2/3 HR+ HER2-negative breast cancer (BC)
2026 · J. Chien, R. M. Mukhtar, et al. · Clinical Cancer Research · 1
Abstract PD11-03: Predicting treatment outcomes in breast cancer from H&E slides using pathology foundation models with multiple instance learning
2026 · A. Sun, S. Venters, et al. · Clinical Cancer Research
Abstract PD6-09: Quantifying the Contribution of Doxorubicin and Cyclophosphamide (AC) to Pathologic Response Following Neoadjuvant Taxane Therapy: Analysis of the I-SPY2 TRIAL
2026 · D. Yee, C. Yau, et al. · Clinical Cancer Research
Abstract PS3-02-09: Recruitment Strategy Success and Challenges in WISDOM 1.0: A Nationwide Risk-Based Breast Cancer Screening Trial
2026 · A. S. Fiscalini, T. Glatt, et al. · Clinical Cancer Research
Abstract PS1-01-09: Real-time monitoring for drug-induced interstitial lung disease with Trastuzumab Deruxtecan and Rilvegostomig combination therapy prevents persistent, symptomatic disease: Safety insights from the I-SPY2.2 platform trial
2026 · T. Kulkarni, R. Nanda, et al. · Clinical Cancer Research
Abstract RF5-04: Germline pathogenic variants in the personalized screening arm of the WISDOM Study: Findings from 23,098 women with no personal history of breast cancer
2026 · K. B. Fergus, K. Ross, et al. · Clinical Cancer Research
Abstract PS5-01-24: Evorpacept (ALX-148) combined with trastuzumab deruxtecan in patients with HER2 positive/HER2low metastatic breast cancer (mBC): results from the PRE-ISPY phase Ib trial
2026 · P. R. POHLMANN, N. Chen, et al. · Clinical Cancer Research
Abstract PS5-12-19: Pre-ispy trial: a phase i/ib oncology platform program (pre-i-spy-p1) nct05868226
2026 · P. R. POHLMANN, D. A. Potter, et al. · Clinical Cancer Research
Abstract PS3-02-24: Completion Rates of Risk Counseling Consultations For Women at High-Risk for Breast Cancer within the WISDOM 1.0 Pragmatic Screening Trial
2026 · J. Moya, K. Ross, et al. · Clinical Cancer Research
Abstract PS3-07-10: Low dose (Z)-endoxifen in the I-SPY2 Endocrine Optimization Pilot
2026 · K. V. Giridhar, M. P. Goetz, et al. · Clinical Cancer Research
Abstract PS3-02-19: Primary Care Provider Input On Personalized Breast Cancer Screening Recommendations in WISDOM 1.0: A Nationwide Risk-Based Breast Cancer Screening Trial
2026 · A. Naeim, A. Stanton, et al. · Clinical Cancer Research
Abstract PS4-09-08: Expanding Diversity through Innovation: Development of the I-SPY ACCESS Initiative for the I-SPY2.2 and DCIS RECAST Clinical Trials
2026 · S. L. Horton, D. A. Idossa, et al. · Clinical Cancer Research
Abstract PS4-04-12: Adaptive selection of p53 mutation metaplastic phenotypes in estrogen-independent progression of ER+ tumors: A mechanism for acquired resistance to hormonal therapy
2026 · H. Mori, H. Moon, et al. · Clinical Cancer Research
Works count: 13
Citation count: 1
H-index: 1
I10-index:
Year
Topic
Type